Zentiva Strengthens European Generic Footprint With Prague Manufacturing Site Investment

Prague (ots/PRNewswire) -

Zentiva is investing EUR 30 million to maximize its manufacturing
site capabilities in Prague. The investment further strengthens
Zentiva's manufacturing footprint and is part of a broader ambition
to become the champion of generics in Europe.

(Logo: https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg )

Thomas Koene, Head of Industrial Operations: "This investment will
focus on the upgrade of our existing manufacturing capabilities, more
specifically on capacity expansion. We are currently producing up to
120 million packages per year in Prague, which we distribute across
Europe. After the carve out, we are accelerating investment in Prague
to support our growth ambition. Our Prague manufacturing site is
a major cornerstone of our company. We have already started to invest
and we are committed to continue this in 2019 with a further
investment of EUR 8 million."

Zentiva is at a unique and exciting crossroads in its journey. A
profound transformation has been started to achieve the full business
potential in a new era of independence, backed by Advent
International.

Ines Windisch, Head of Corporate Affairs & Human Resources added:
"The growth of our organization brings new opportunities for our
people and positions. This great transformation will attract the best
talent and retain our team to secure our success for future
generations. We are currently employing more than 600 people in our
Prague site, who are dedicated to producing high-quality medicines
that support peoples' daily healthcare needs."

About Zentiva

At Zentiva we aspire that healthcare should be a right and not a
privilege. More than ever, people need better access to healthcare.

Today, the everyday solutions that we all depend on truly count as
a vital foundation of healthy living. Zentiva works for the people
living in Europe. Standing side-by-side with healthcare
professionals, pharmacists and Health System decision-makers, we have
the same sense of social obligation to help lower costs and improve
access to healthcare.

With more than 2,500 people across Europe and 2 production sites
in Prague and Bucharest we strive to be the champions of Generics and
OTC medicines to better support people's daily healthcare needs.

Media contact:

Mounira Lemoui, Communication Business Partner

Zentiva Group, a.s.,

Cell: +420-727-873-159

U Kabelovny 130 - 102 37 PRAGUE - Czech Republic

www.zentiva.com

ots Originaltext: Zentiva
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: Zentiva, übermittelt durch news aktuell